fluorodeoxyglucose f18 has been researched along with Prostatic Neoplasms, Castration-Resistant in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 9 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bauckneht, M; Campi, C; Chiola, S; Cremante, M; D'Amico, F; Donegani, MI; Fornarini, G; Lai, R; Lanfranchi, F; Marini, C; Miceli, A; Morbelli, S; Piana, M; Raffa, S; Rebuzzi, SE; Sambuceti, G; Schenone, D; Zanardi, E | 1 |
| Freedland, SJ; Gan, H; Liu, C; Ni, X; Pan, J; Song, S; Wang, B; Wang, Q; Wei, Y; Wu, J; Ye, D; Zhang, T; Zhao, J; Zhu, Y | 1 |
| Azad, AA; Buteau, JP; Davis, ID; Emmett, L; Francis, RJ; Hofman, MS; Iravani, A; Joshua, AM; Lee, ST; Martin, AJ; McJannett, MM; Sandhu, S; Scott, AM; Stockler, MR; Williams, SG; Zhang, AY | 1 |
| Akdogan, B; Aksoy, S; Caglar, M; Erman, M; Karabulut, E; Telli, T; Tuncel, M | 1 |
| D'Alessandria, C; Eiber, M; Haller, B; Heck, M; Karimzadeh, A; Knorr, K; Nekolla, S; Rauscher, I; Solaris, E; Tauber, R; Weber, WA | 1 |
| Burger, IA; Ghafoor, S; Vargas, AH | 1 |
| Bakshi, G; Banerjee, S; Basu, S; Joshi, A; Parghane, RV; Prabhash, K; Suman, S; Talole, S | 1 |
| Ezziddin, S; Giesel, FL; Haberkorn, U; Khreish, F; Kratochwil, C; Rosar, F | 1 |
| Freedland, SJ; Gan, H; Hu, S; Liu, C; Ma, X; Meng, J; Pan, J; Song, S; Wan, F; Wang, B; Wei, Y; Xu, X; Ye, D; Zhang, Y; Zhu, Y | 1 |
| Albano, D; Baldari, S; Bauckneht, M; Berruti, A; Bertagna, F; De Biasi, V; Donegani, MI; Durmo, R; Fornarini, G; Giubbini, R; Laudicella, R; Miceli, A; Morbelli, S; Sambuceti, G; Versari, A | 1 |
| Has-Simsek, D; Isik, EG; Kuyumcu, S; Sanli, O; Sanli, Y | 1 |
| Beauregard, JM; Bergeron, M; Fradet, V; Fradet, Y; Lacombe, L; Morin, F; Nguile Makao, M; Pouliot, F | 1 |
| Beattie, B; Blanc-Autran, E; Fine, SW; Fox, JJ; Gavane, SC; Gönen, M; Humm, JL; Larson, SM; Lewis, JS; Morris, MJ; Nehmeh, S; Osborne, JR; Sawyers, CL; Scher, HI; Schöder, H; Solomon, SB; Vargas, HA; Veach, D; Weber, WA | 1 |
| Beauregard, JM; Bergeron, M; Blouin, AC; Buteau, FA; Duchesnay, N; Dujardin, T; Fradet, V; Fradet, Y; Lacombe, L; Lavallée, E; Makao-Nguile, M; Pouliot, F; Tiguert, R | 1 |
| Jeraj, R; Liu, G; Perlman, S; Simoncic, U; Staab, MJ; Straus, JE | 1 |
| Beer, TM; Courtney, KD; Elfiky, AA; Kantoff, P; Loda, M; Manola, JB; Oh, WK; Priolo, C; Ross, R; Ryan, CW; Taplin, ME; Van den Abbeele, AD; Yap, JT | 1 |
| Araujo, JC; Etchebehere, EC; Fox, PS; Macapinlac, HA; Rohren, EM; Swanston, NM | 1 |
| Jeraj, R; Liu, G; Perlman, S; Simoncic, U | 1 |
1 review(s) available for fluorodeoxyglucose f18 and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Multimodality Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Carboxylic Acids; Choline; Cyclobutanes; Disease Progression; Fluorodeoxyglucose F18; Glutamate Carboxypeptidase II; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Multiparametric Magnetic Resonance Imaging; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radionuclide Imaging; Theranostic Nanomedicine; Tomography, X-Ray Computed; Whole Body Imaging | 2019 |
4 trial(s) available for fluorodeoxyglucose f18 and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [
Topics: Adolescent; Adult; Australia; Fluorodeoxyglucose F18; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy.
Topics: Dipeptides; Fluorodeoxyglucose F18; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Fluorodeoxyglucose F18; Glycolysis; Humans; Immunohistochemistry; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Prognosis; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2018 |
A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Drug Administration Schedule; Everolimus; Fluorodeoxyglucose F18; Humans; Male; Maximum Tolerated Dose; Middle Aged; Positron-Emission Tomography; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2015 |
13 other study(ies) available for fluorodeoxyglucose f18 and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223.
Topics: Androgen Antagonists; Benchmarking; Fluorodeoxyglucose F18; Humans; Male; Muscle, Skeletal; Positron Emission Tomography Computed Tomography; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2022 |
The prevalence and prognosis of next-generation therapeutic targets in metastatic castration-resistant prostate cancer.
Topics: Fluorodeoxyglucose F18; Humans; Male; Positron Emission Tomography Computed Tomography; Prevalence; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2022 |
Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with
Topics: Fluorodeoxyglucose F18; Humans; Male; Positron Emission Tomography Computed Tomography; Prognosis; Progression-Free Survival; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Therapeutic efficacy, prognostic variables and clinical outcome of
Topics: Aged; Aged, 80 and over; Antigens, Surface; Dipeptides; Fluorodeoxyglucose F18; Gallium Radioisotopes; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Positron Emission Tomography Computed Tomography; Prognosis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2019 |
Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease.
Topics: Fluorodeoxyglucose F18; Heterocyclic Compounds, 1-Ring; Humans; Male; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant | 2020 |
A Prospective Trial of
Topics: Aged; Androgen Antagonists; Disease Progression; Drug Resistance, Neoplasm; Fluorodeoxyglucose F18; Gallium Isotopes; Gallium Radioisotopes; Humans; Kallikreins; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Tumor Burden | 2020 |
The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Fluorodeoxyglucose F18; Humans; Italy; Male; Middle Aged; Neoplasm Grading; Positron Emission Tomography Computed Tomography; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2021 |
Fibroblast Activation Protein-Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT.
Topics: Fibroblasts; Fluorodeoxyglucose F18; Gallium Isotopes; Gallium Radioisotopes; Humans; Male; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prostatic Neoplasms, Castration-Resistant | 2022 |
Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Fluorodeoxyglucose F18; Humans; Male; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2017 |
Increased Prostate Cancer Glucose Metabolism Detected by
Topics: Aged; Case-Control Studies; Disease-Free Survival; Fluorodeoxyglucose F18; Glucose; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Preoperative Period; Prognosis; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Risk Assessment; Severity of Illness Index | 2019 |
Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Clinical Trials, Phase III as Topic; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Prostatic Neoplasms, Castration-Resistant; Pyrrolidines; Sodium Fluoride; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bone and Bones; Bone Neoplasms; Disease-Free Survival; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Odds Ratio; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Reproducibility of Results; Research Design; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Optimizing an 18F-NaF and 18F-FDG cocktail for PET assessment of metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Positron-Emission Tomography; Prostatic Neoplasms, Castration-Resistant; Sodium Fluoride; Tomography, X-Ray Computed | 2015 |